SENSEI BIOTHERAPEUTICS INC (SNSE) Stock Analyst Ratings
NASDAQ:SNSE - Nasdaq - US81728A1088 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 88% to SNSE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 4.08. This target is 1086.05% above the current price.
SNSE was analyzed by 10 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about SNSE.
In the previous month the buy percentage consensus was at a similar level.
SNSE was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-03-28 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-03-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-03 | Citigroup | Reiterate | Buy -> Buy |
| 2024-05-24 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2024-05-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-14 | Stephens & Co. | Initiate | Overweight |
| 2023-12-04 | HC Wainwright & Co. | Initiate | Buy |
| 2022-12-13 | Citigroup | Initiate | Buy |
| 2022-10-03 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2022-03-10 | Piper Sandler | Maintains | Overweight |
| 2021-07-01 | Berenberg | Downgrade | Buy -> Hold |
| 2021-06-29 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2021-03-01 | Oppenheimer | Initiate | Outperform |
| 2021-03-01 | Piper Sandler | Initiate | Overweight |